JusticeItaly Official institution

Italy authorizes Cabazitaxel Aurobindo cancer infusion medicine

Italy's medicines agency AIFA has authorized Cabazitaxel Aurobindo, a generic cabazitaxel concentrate for infusion, in a decision dated 20 October 2026. The license is held by Eugia Pharma (Malta) Limited, and the medicine is available in packs of one, five and ten glass vials. Cabazitaxel is a cancer drug given by intravenous drip, and the medicine is limited to hospital use.

This summary was generated by AI; the official source prevails.

What does it mean?

This means a cabazitaxel infusion medicine can now be legally sold in Italy under the Cabazitaxel Aurobindo name. It is given through a drip in hospitals, not sold at pharmacies for home use.

Who is affected?

Hospital patients who need cabazitaxel treatment and the doctors and hospitals that prescribe and give it.